Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | PTGIR | P43119 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242218 | 0.90 | ACHE (0.42) | ACHEPTGIRLPAR1LPAR5KMT2A | |
| SCHEMBL4234325 | 0.90 | ACHE (0.41) | ACHEPTGIRLPAR1LPAR5KMT2A | |
| SCHEMBL4233453 | 0.89 | ACHE (0.39) | ACHEPTGIRLPAR1LPAR5KMT2A | |
| SCHEMBL4233438 | 0.78 | ACHE (0.37) | ACHEPTGIRMCHR1FGFR1L3MBTL1 | |
| SCHEMBL4229108 | 0.77 | MCHR1 (0.36) | ACHEPTGIRKMT2AMCHR1FGFR1 | |
| SCHEMBL4686461 | 0.77 | ALDH1A1 (0.40) | ACHELPAR1LPAR5KMT2AMEN1 | |
| SCHEMBL4686937 | 0.77 | POLB (0.43) | ACHEPTGIRLPAR1LPAR5KMT2A | |
| SCHEMBL4686834 | 0.73 | CCR3 (0.43) | KMT2AMEN1GAACCR3MCHR1 | |
| SCHEMBL4226786 | 0.73 | SMN1; SMN2 (0.42) | PTGIRKMT2AMEN1GAACCR3 | |
| SCHEMBL13699157 | 0.73 | CHRM1 (0.44) | PTGIRLPAR1LPAR5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | ACHE 560/4885PTGIR 526/4885LPAR1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.